Chicago, Illinois - Adding another type of cholesterol-lowering drug to statin therapy can better prevent heart attacks and strokes in high-risk patients with acute coronary syndrome (ACS), according to a large, long-term study presented at the American Heart Association’s Scientific Sessions 2014.

Chicago, Illinois - The American Heart Association awarded its Basic Research Prize for 2014 to Ande Terzic, M.D., Ph.D., of the Mayo Clinic “for pioneering applications of emerging technologies to advance the diagnosis and treatment of cardiovascular disorders.”Terzic received the prize during opening ceremonies of the AHA’s Scientific Sessions 2014 at Chicago’s McCormick Place.

Imperial, California - Smoking is one of the rare things in life when it’s OK to be a quitter. The American Cancer Society Great American Smokeout takes place on the third Thursday of November each year. This year, that’s November 20, which marks the 39th Great American Smokeout. Smokers are encouraged to use the date to make a plan to quit, or to plan in advance and begin their path to health by quitting on that day. Quitting even for one day can be an important step toward a healthier life - one that can significantly reduce cancer risk.

Dallas, Texas - Groundbreaking research from UT Southwestern Medical Center shows that cholesterol efflux capacity (cholesterol efflux), which measures HDL cholesterol function, appears to be a superior indicator of cardiovascular risk and a better target for therapeutic treatments than standard measurements of HDL. Current measurement methods reflect only the circulating levels of HDL and not the functional properties of this lipoprotein.

Washington, DC - The U.S. Department of Health and Human Services today issued a Notice of Proposed Rulemaking (NPRM), which proposes regulations to implement reporting requirements for clinical trials that are subject to Title VIII of the Food and Drug Administration Amendments Act of 2007 (FDAAA).

Washington, DC - Using two drugs was no more effective than a single drug in slowing disease progression in people with autosomal dominant polycystic kidney disease (ADPKD), according to two studies funded by the National Institutes of Health (NIH). One of the studies also showed that rigorous blood pressure treatment slowed growth of kidney cysts, a marker of ADPKD, but had little effect on kidney function compared to standard blood pressure treatment.